文献速递血栓与止血

溶血性尿毒症综合征与非典型溶血性尿毒症综合征

HUS and atypical HUS.
PubMed 文献 · Blood · 2017-04-17

本文综述了典型溶血性尿毒症综合征(STEC-HUS)、非典型HUS(aHUS)及继发性HUS的发病机制异同。共同核心为补体激活、内皮细胞损伤、血小板活化与血栓形成的恶性循环;补体抑制治疗可阻断该过程,但对DGKε突变者及部分STEC-HUS或继发性HUS患者通常无效。

要点

  • HUS分为典型(STEC感染)、非典型(补体失调)和继发性(伴发疾病)三类。
  • 30%至50%的HUS患者无可检测的补体缺陷,部分存在DGKε活性受损、钴胺素C缺乏或纤溶酶原缺乏。
  • 补体抑制治疗可阻断多数aHUS患者的恶性循环,但对DGKε突变者及部分STEC-HUS或继发性HUS患者通常无效。

核心结论

  • 补体激活、内皮细胞损伤、血小板活化和血栓形成的恶性循环似乎是各型HUS的共同发病机制。
  • 补体抑制治疗可阻断该过程,在多数aHUS患者中有效,但在DGKε突变患者及部分STEC-HUS或继发性HUS患者中通常无效。

研究设计与样本

  • 综述,讨论STEC-HUS、aHUS和继发性HUS发病机制的差异与相似之处。

主要发现

  • 典型HUS(即STEC-HUS)发生于产志贺毒素大肠埃希菌(STEC)胃肠道感染之后。
  • aHUS主要与导致补体激活失调的突变或自身抗体相关。
  • 在30%至50%无可检测补体缺陷的HUS患者中,部分存在二酰甘油激酶ε(DGKε)活性受损、钴胺素C缺乏或纤溶酶原缺乏。
  • 部分患者为继发性HUS,伴发自身免疫、移植、肿瘤、感染、某些细胞毒性药物或妊娠等疾病或触发因素。
  • STEC-HUS、aHUS和继发性HUS的共同发病特征为同时发生内皮细胞损伤、血管内溶血和血小板活化,导致促凝血状态、微血栓形成和组织损伤。

临床怎么用

  • 理解不同形式HUS的发病机制可能对临床实践有帮助。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by intravascular hemolysis, thrombocytopenia, and acute kidney failure. HUS is usually categorized as typical, caused by Shiga toxin-producing Escherichia coli (STEC) infection, as atypical HUS (aHUS), usually caused by uncontrolled complement activation, or as secondary HUS with a coexisting disease. In recent years, a general understanding of the pathogenetic mechanisms driving HUS has increased. Typical HUS (ie, STEC-HUS) follows a gastrointestinal infection with STEC, whereas aHUS is associated primarily with mutations or autoantibodies leading to dysregulated complement activation. Among the 30% to 50% of patients with HUS who have no detectable complement defect, some have either impaired diacylglycerol kinase ε (DGKε) activity, cobalamin C deficiency, or plasminogen deficiency. Some have secondary HUS with a coexisting disease or trigger such as autoimmunity, transplantation, cancer, infection, certain cytotoxic drugs, or pregnancy. The common pathogenetic features in STEC-HUS, aHUS, and secondary HUS are simultaneous damage to endothelial cells, intravascular hemolysis, and activation of platelets leading to a procoagulative state, formation of microthrombi, and tissue damage. In this review, the differences and similarities in the pathogenesis of STEC-HUS, aHUS, and secondary HUS are discussed. Common for the pathogenesis seems to be the vicious cycle of complement activation, endothelial cell damage, platelet activation, and thrombosis. This process can be stopped by therapeutic complement inhibition in most patients with aHUS, but usually not those with a DGKε mutation, and some patients with STEC-HUS or secondary HUS. Therefore, understanding the pathogenesis of the different forms of HUS may prove helpful in clinical practice.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Jokiranta TS. HUS and atypical HUS. Blood. 2017. PMID: 28416508. doi:10.1182/blood-2016-11-709865

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。